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Introduction: 
The MU Biodesign and Innovation Program (MUBIP) is focused on improving 
health care through invention and implementation of new medical technologies.  
The focus of the program is formal educational training of three fellows with a 
focus on biodesign and innovation.  Additionally, the program is dedicated to the 
development and facilitation of interdisciplinary collaboration between faculty and 
students to increase innovation at the University of Missouri. 
Background: 
With the financial support of the Department of Surgery, the School of 
Engineering and the Missouri Technology Corporation (MTC) the MUBIP is in its 
3rd successful year.  The program brings the brightest young minds with an M.D. 
degree, an engineer with a masters or PhD, and a business professional with an 
MBA together as a design team.  The fellowship year structure is divided into 
three phases.  Phase 1 is clinical immersion; Phase 2 engineering design and 
development, finishing with Phase 3, business practices.  Each phase is 
approximately 4 months with overlap throughout the year.  In addition to 
observation and hands on training in each phase the fellows attend lectures 
related to the biodesign process.  Lectures are presented by faculty and staff 
from the Department of Surgery, College of Engineering, entrepreneurs, angel 
fund investors, venture capitalists, industry leaders, founders from startup 
companies, and other successful biodesign related individuals from the 
community and nationwide.  
Results:  
The MUBIP Fellowship had the first group of fellows enter in July of 2007.  The 
2007-2008 fellows identified over 200 needs during their clinical immersion 
phase. After filtering the solutions, a novel hernia mesh design was chosen by 
the fellows as the main focus for the engineering phase resulting in a provisional 
patent application was filed and is currently undergoing investigation for 
commercialization.  The second year, 2008-2009, team identified over 200 needs 
and identified fifteen for innovation. MUBIP comprised 1/8 of all 2009 inventions 
disclosed at the Columbia Campus. These innovations consisted of 9 minimally 
invasive devices, 3 real time patient monitoring devices, 2 minimally invasive 
cosmetic devices, and 1 laparoscopic trainer, many of which are in different 
phases of development and commercialization.  Our current fellows completed 
their clinical immersion phase and identified over 200 needs; each fellow has 
identified a “pet” project and a group project.  The addition of a “super-fellow” this 
year has allowed for continuing innovation.  This fellow focuses on the 
development and commercialization of the prior year’s fellowship projects. The 
super-fellow has increased undergraduate, graduate and faculty collaboration 
with the School of Engineering and the School of Medicine. 
Conclusion:   
The MUBIP is a nationally recognized premier program focused on a team 
approach of educating physicians, engineers, and business graduates on the 
process of biodesign and becoming successful entrepreneurs.   Our early results 
indicate continued success and growth of the MUBIP.   
 
